Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia

Haematologica

Volumn 85, Issue 3, 2000, Pages 304-313

  Carella, Angelo M ^a   Giralt, Sergio ^b   Slavin, Shimon ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Chimerism; Hematologic neoplasias; Low intensity regimens

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; IDARUBICIN; MYELOABLATIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGRAFT; ARTICLE; CHIMERA; CLINICAL ARTICLE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALE; MYELODYSPLASTIC SYNDROME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PILOT PROJECTS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 0034115811     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89:4531-6.
2. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91:756-63.
3. Slavin S, Or R, Naparstek E, et al. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood 1988; 72:407a.
4. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23:1553-62.
5. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87:2195-204.
6. Kolb HJ, Mittermüller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76:2462-5.
7. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330:100-6.
8. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86:2041-50.
9. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86:1261-8.
10. Giralt S, Hester J, Huh Y, et al. CDS-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86:4337-43.
11. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15:433-44.
12. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplantated SCID mice. Blood 1994; 83:2360-7.
13. Ferrara J. Mechanisms of graft-versus-leukemia/graft-versus-host-disease. In: Educational Book, ASCO Meeting 1997. p. 84-7.
14. Van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83:3377-83.
15. Rondòn G, Giralt S, Huh Y, et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996; 18:669-72.
16. van Besien K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92:1832-6.
17. Khouri IF, Przepiorka D, van Besien K, et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-verus-host disease. Br J Haematol 1997; 97:466-73.
18. Childs RW, Clave E, Tisdale J, et al. Successful treatment of metastatic renal cell carcinoma with a non-myeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999; 17:2044-50.
19. Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88:1501-8.
20. Ueno NT, Rondòn G, Mirza NQ, et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998; 16:986-93.
21. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89:3049-54.
22. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73:1720-8.
23. Carella AM, Lerma E, Dejana A, et al. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Haematologica 1998; 83:904-9.
24. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74:19-25.
25. Khouri IF, Keating M, Korbling M, et al. Transplantlite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16:2817-24.
26. Storb R. Nonmyeloablative preparative regimens: experimental data and clinical practice. ASCO: 1999 Educational Book, pp. 241, 55th Annual Meeting, May 15-18, Atlanta.
27. Slavin S, Nagler A, Naparstek E, et al. Allogeneic non-myeloablative stem cell transplantation (NST) as an emerging new modality for immunotherapy malignant and non-malignant disorders. Blood 1998; 92(Suppl.1):519a.
28. Nagler A, Or R, Naparstek E, et al. Matched unrelated bone marrow transplantation (BMT) using a non-myeloablative conditioning regimen. American Society of Hematology (ASH). November 4-8, 1998. Florida USA Blood 92:10(1) Abs. #1185; pp. 289a.
29. Nagler A, Or R, Naparstek E, et al. Secondary allogeneic stem cell transplantation (alloSCT) using a non-myeloablative conditioning regimen for patients with hematological malignancies. American Society of Hematology (ASH). November 4-8, 1998. Florida USA. Blood 92:10(1) abst. #553: pp 137a.
30. Sykes M, Preffer F, McAfee S, et al. Mixed lympho-haemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mis-matched bone marrow transplantation. Lancet 1999; 353:1755-9.
31. Carella AM, Lerma E, Corsetti MT, et al. Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone. Br J Haematol 1998; 103:565-7.
32. Mc Sweney P, Storb R. Mixed chimerism: preclinical and clinical applications. Biology Blood Marrow Transplant 1999; 5:192-203.